⁹⁹Tc-Methylene Diphosphonate Treatment is Safe and Efficacious for Osteoporosis in Postmenopausal Differentiated Thyroid Cancer Patients Undergoing TSH Suppression: A Three-Center Non-Randomized Clinical Study

References

• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.0020
   PubMed Web of Science ®Google Scholar
• Gao M. Diagnosis and treatment guideline for thyroid nodules and differentiated cancer. Cancer Clin China. 2012;17:1249–1272.
   Google Scholar
• Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010;20(2):135–146. doi:10.1089/thy.2009.0311
   PubMed Web of Science ®Google Scholar
• Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab. 2008;93(4):1167–1169. doi:10.1210/jc.2007-2228
   PubMed Web of Science ®Google Scholar
• Huo Y, Wang D, Wu S, Wang H, Ma C. The impact of TSH suppression treatment on bone mineral density in postmenopausal patients with differentiated thyroid cancer. Chin J Nucl Med Mol Imaging. 2017;37(4):212–215.
   Google Scholar
• Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab. 1991;72(6):1184–1188. doi:10.1210/jcem-72-6-1184
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Hamdy NA, Romijn JA, Smit JW. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Thyroid. 2006;16(6):583–591. doi:10.1089/thy.2006.16.583
   PubMed Web of Science ®Google Scholar
• Karner I, Hrgović Z, Sijanović S, et al. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res. 2005;10(11):480–488.
   PubMed Web of Science ®Google Scholar
• Kim MK, Yun KJ, Kim MH, et al. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone. 2015;71:101–105. doi:10.1016/j.bone.2014.10.009
   PubMed Web of Science ®Google Scholar
• Kung AW, Lorentz T, Tam SC. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clin Endocrinol. 1993;39(5):535–540. doi:10.1111/j.1365-2265.1993.tb02405.x
   PubMed Web of Science ®Google Scholar
• Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery. 2011;150(6):1250–1257. doi:10.1016/j.surg.2011.09.013
   PubMed Web of Science ®Google Scholar
• Cellini M, Rotondi M, Tanda ML, et al. Skeletal health in patients with differentiated thyroid carcinoma. J Endocrinol Invest. 2021;44(3):431–442. doi:10.1007/s40618-020-01359-6
   PubMed Web of Science ®Google Scholar
• Fu Q, Feng P, Sun LY, et al. A double-blind, double-dummy, randomized controlled, multicenter trial of 99Tc-methylene diphosphonate in patients with moderate to severe rheumatoid arthritis. Chin Med J. 2021;134(12):1457–1464. doi:10.1097/CM9.0000000000001527
   PubMed Web of Science ®Google Scholar
• Gong W, Dou H, Liu X, Sun L, Hou Y. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis. Clin Exp Pharmacol Physiol. 2012;39(10):886–893. doi:10.1111/j.1440-1681.2012.12006.x
   PubMed Web of Science ®Google Scholar
• Chen J, Lan Y, He Y, et al. 99Tc-MDP-induced human osteoblast proliferation, differentiation and expression of osteoprotegerin. Mol Med Rep. 2017;16(2):1801–1809. doi:10.3892/mmr.2017.6839
   PubMed Web of Science ®Google Scholar
• Shen S, Wang W, Yang C, Xu B, Zeng L, Qian Y. Effect of technetium-99 conjugated with methylene diphosphonate ((99) Tc-MDP) on OPG/RANKL/RANK system in vitro. J Oral Pathol Med. 2019;48(2):129–135.
   PubMed Web of Science ®Google Scholar
• Duan Y. Clinical analysis of yunke in the treatment of primary osteoporosis. Chin Med Guide. 2011;9(18):259–260.
   Google Scholar
• Guo Z, Zhang M, Zhang C. Clinical observation of yunke in treating 93 cases of postmenopausal osteoporosis. Chin J Osteoporos. 2012;18(4):358–360.
   Google Scholar
• Liu H, Guo H, Guo S, Wang J, Ye Y, Ma C. Novel treatment of 99Tc-MDP improves clinical and radiographic results for patients with osteochondral lesions of the talus. Q J Nucl Med Mol Imaging. 2019;63(2):199–206. doi:10.23736/S1824-4785.16.02872-7
   PubMed Web of Science ®Google Scholar
• Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010;363(21):2027–2035. doi:10.1056/NEJMct1004903
   PubMed Web of Science ®Google Scholar
• Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005;353(6):595–603. doi:10.1056/NEJMcp043801
   PubMed Web of Science ®Google Scholar
• D’Amelio P, Grimaldi A, Cristofaro MA, et al. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 2010;21(10):1741–1750. doi:10.1007/s00198-009-1129-1
   PubMed Web of Science ®Google Scholar
• Siebelt M, Waarsing JH, Groen HC, et al. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression. Bone. 2014;66:163–170. doi:10.1016/j.bone.2014.06.009
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang L, Liu Y, et al. Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw. Calcif Tissue Int. 2012;91(6):400–408. doi:10.1007/s00223-012-9649-7
   PubMed Web of Science ®Google Scholar
• Shi L, Ning Y, Xu L, Li J, Zhang X. Technetium-99 conjugated with methylene diphosphonate ameliorates glucocorticoid induced osteoporosis by inhibiting osteoclastogenesis. Biomed Res Int. 2018;2018:7902760. doi:10.1155/2018/7902760
   PubMed Web of Science ®Google Scholar
• Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555–1565. doi:10.1210/jc.2009-1947
   PubMed Web of Science ®Google Scholar
• Bi Y, Gao Y, Ehirchiou D, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol. 2010;177(1):280–290. doi:10.2353/ajpath.2010.090592
   PubMed Web of Science ®Google Scholar
• Khosla S, Cauley JA, Compston J, et al. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. 2017;32(3):424–430. doi:10.1002/jbmr.3074
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822. doi:10.1056/NEJMoa067312
   PubMed Web of Science ®Google Scholar